Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Camidge on Inhibiting Initial Activating EGFR Mutations and the T790M Resistance Mutation

October 31st 2014

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

Second-Line Treatment in NSCLC

October 30th 2014

Discussing Maintenance Therapy in NSCLC

October 30th 2014

Strategies for Delivering Maintenance Therapy in NSCLC

October 30th 2014

Maintenance Therapy in NSCLC

October 30th 2014

First-, Second-, and Third-Line Treatment for NSCLC

October 30th 2014

Adjuvant Versus Neoadjuvant Chemotherapy for NSCLC

October 30th 2014

Histology and NSCLC Treatment

October 30th 2014

Utilizing Treatment Regimens in NSCLC

October 30th 2014

Current Treatment Landscape for NSCLC

October 30th 2014

Molecular Profiling Reveals Potential Targets in SCLC, Lung NETs

October 30th 2014

Molecular profiling has revealed several tumor markers that could be utilized as therapeutic targets for patients with small cell lung cancer (SCLC) or lung neuroendocrine tumors (NETs).

PCP Knowledge Gap Could Affect Lung Cancer Screening Implementation

October 30th 2014

A new study suggests a knowledge gap in Primary Care Providers' familiarity with screening guidelines could also be a barrier to successful implementation.

Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6

October 30th 2014

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

Reducing Lung Biopsies May Cut Costs, Improve Patient Outcomes

October 30th 2014

Biopsies were found to be the most costly tool used in lung cancer diagnosis, and may be performed too frequently based on negative test results and adverse events.

Dr. Gandara Discusses the Future of Clinical Trial Designs

October 30th 2014

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

FDA Grants Breakthrough Therapy Designation to Pembrolizumab for NSCLC

October 27th 2014

The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of patients with non-small cell lung cancer (NSCLC) who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.

PARP Inhibitor Shows Potential in Squamous Cell Lung Cancer

October 26th 2014

Suresh S. Ramalingam, MD, discusses results from a phase II trial exploring the potential of veliparib as a treatment for patients with squamous cell NSCLC.

New Treatment Strategies Emerge for Non-Small Cell Lung Cancer

October 19th 2014

The treatment of patients with non-small cell lung cancer (NSCLC) who harbor an actionable mutation in EGFR or ALK continues evolve, as clinical trials begin exploring next-generation agents and combination strategies.

Treatment Selection in Metastatic Prostate Cancer

October 16th 2014

Convincing Long-Term Survival With Abiraterone in mCRPC

October 16th 2014

x